(Q40874693)

24 September 2017

1 reference

title

Oral idarubicin--an anthracycline derivative with unique properties (English)

1 reference

24 September 2017

M Goebel

1

1 reference

24 September 2017

publication date

1 January 1993

1 reference

24 September 2017

1 reference

24 September 2017

volume

66

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

33-43

1 reference

Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer

24 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01737687

Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions

21 January 2018

1 reference

12 December 2020

Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors

1 reference

12 December 2020

Phase II study of idarubicin in extensive-disease non-small-cell lung cancer

1 reference

12 December 2020

Idarubicin plus Cytarabine versus Doxorubicin plus Cytarabine in Induction Therapy for Acute Non- Lymphoid Leukaemia: A Randomized Trial

1 reference

12 December 2020

Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo)

1 reference

12 December 2020

Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study

1 reference

12 December 2020

Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide

1 reference

12 December 2020

The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study

1 reference

12 December 2020

Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin

1 reference

12 December 2020

Oral idarubicin in elderly patients with acute myeloid leukemia.

1 reference

12 December 2020

4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study

1 reference

12 December 2020

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

1 reference

12 December 2020

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Phase II study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma

1 reference

12 December 2020

Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study

1 reference

12 December 2020

Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

1 reference

12 December 2020

[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route]

1 reference

12 December 2020

Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients. A phase II study

1 reference

12 December 2020

Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study

1 reference

12 December 2020

Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study

1 reference

12 December 2020

Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia.

1 reference

12 December 2020

Idarubicin in advanced breast cancer: a phase II study

1 reference

12 December 2020

Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma

1 reference

12 December 2020

Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society

1 reference

12 December 2020

New anthracycline analogs in advanced breast cancer

1 reference

12 December 2020

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

1 reference

12 December 2020

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

1 reference

12 December 2020

Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro

1 reference

12 December 2020

Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes

1 reference

12 December 2020

Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin

1 reference

12 December 2020

Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients

1 reference

12 December 2020

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial

1 reference

12 December 2020

Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e

1 reference

12 December 2020

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

1 reference

12 December 2020

Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin

1 reference

12 December 2020

Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells

1 reference

12 December 2020

Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors

1 reference

12 December 2020

Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

1 reference

12 December 2020

Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies

1 reference

12 December 2020

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology

1 reference

12 December 2020

Oral idarubicin in measurable gastric cancer

1 reference

12 December 2020

Bioavailability and pharmacology of oral idarubicin

1 reference

12 December 2020

Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients

1 reference

12 December 2020

Oral idarubicin as treatment for advanced myelodysplastic syndrome

1 reference

12 December 2020

Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol

1 reference

12 December 2020

A phase II study of idarubicin and prednisone in multiple myeloma.

1 reference

12 December 2020

Pharmacokinetic study of intravenous and oral idarubicin in cancer patients

1 reference

12 December 2020

Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients

1 reference

12 December 2020

A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma

1 reference

12 December 2020

1 reference

12 December 2020

A phase II trial of oral 4'demethoxydaunorubicin in advanced colorectal carcinoma

1 reference

12 December 2020

Oral idarubicin in non-Hodgkin's lymphomas

1 reference

12 December 2020

Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers

1 reference

12 December 2020

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

1 reference

12 December 2020

Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer

1 reference

12 December 2020

Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease

1 reference

12 December 2020

Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts

1 reference

12 December 2020

Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer

1 reference

12 December 2020

Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients

1 reference

12 December 2020

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

1 reference

12 December 2020

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1 reference

12 December 2020

A phase II trial of oral 4'demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

1 reference

12 December 2020

Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma

1 reference

12 December 2020

A pilot study of oral idarubicin in metastatic melanoma.

1 reference

12 December 2020

Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells

1 reference

12 December 2020

Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients

1 reference

12 December 2020

Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia

1 reference

12 December 2020

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

12 December 2020

Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia

1 reference

12 December 2020

A hypothesis concerning possible new derivatives of daunorubicin and adriamycin with enhanced DNA-binding properties

1 reference

12 December 2020

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)

1 reference

12 December 2020

Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines

1 reference

12 December 2020

Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells

1 reference

12 December 2020

A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies

1 reference

12 December 2020

Oral idarubicin in adult acute leukemia: a preliminary experience

1 reference

12 December 2020

Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients

1 reference

12 December 2020

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Comparative study of demethoxydaunorubicin with other anthracyclines on generation of oxygen radicals and clonogenic survival of fibroblasts

1 reference

12 December 2020

Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer

1 reference

12 December 2020

Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma

1 reference

12 December 2020

Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.

1 reference

12 December 2020

Antitumor activity of 4-demethoxydaunorubicin administered orally

1 reference

12 December 2020

Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

1 reference

12 December 2020

Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.

1 reference

12 December 2020

Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.

1 reference

12 December 2020

Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma

1 reference

12 December 2020

Weekly oral idarubicin in advanced prostatic cancer. A phase II study

1 reference

12 December 2020

Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia

1 reference

12 December 2020

A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.

1 reference

12 December 2020

Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

1 reference

12 December 2020

Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01737687

1 reference

24 September 2017

1 reference